Clinical Trial Update: Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564) [Phase 3]

View source ↗

Summary

Phase 3 trial assessing pembrolizumab as adjuvant therapy after nephrectomy in renal cell carcinoma has completed, with results posted in 2021. The trial evalua…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Renal Cell Carcinoma | Phase 3 | Status: COMPLETED | Results posted: 2021-12-28